Abstract: Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human FXII and inhibiting FXII activity, resulting in safe anti-inflammatory and anti-thrombotic effects.
Type:
Application
Filed:
November 27, 2019
Publication date:
March 24, 2022
Applicants:
Oregon Health & Science University, Aronora, Inc.
Inventors:
Michael Wallisch, Andras Gruber, Erik I. Tucker, Christina U. Lorentz
Abstract: Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and/or adversely affects disease outcome.
Type:
Application
Filed:
July 16, 2019
Publication date:
September 9, 2021
Applicants:
Aronora, Inc., Oregon Health & Science University, Ionis Pharmaceuticals, Inc.
Inventors:
Andras Gruber, Erik Tucker, Brett P. Monia, Alexey Revenko
Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
May 19, 2020
Assignees:
Bayer Pharma Aktiengesellschaft, ARONORA INC.
Inventors:
Andreas Wilmen, Anja Buchmüller, Erik Tucker
Abstract: The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin, and the thrombin produced by this method.
Type:
Grant
Filed:
February 5, 2014
Date of Patent:
December 17, 2019
Assignees:
AbSci LLC, Aronora Inc.
Inventors:
Sean McClain, Mark Valasek, Andras Gruber
Abstract: The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.
Type:
Application
Filed:
September 18, 2017
Publication date:
July 25, 2019
Applicants:
Bayer Pharma Aktiengesellschaft, ARONORA INC.
Inventors:
Andreas WILMEN, Anja BUCHMÜLLER, Erik TUCKER
Abstract: Provided are antibodies that selectively bind to and inhibit activation of coagulation factor XII. Methods of treatment employing these antibodies are described herein.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
February 21, 2017
Assignees:
VANDERBILT UNIVERSITY, ARONORA, INC., OREGON HEALTH & SCIENCE UNIVERSITY
Inventors:
Andras Gruber, David Gailani, Philberta Leung, Anton Matafonov